Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial
tumours, which tend to recur but are generally not life threatening, and 30% presenting as …

Bladder cancer—the tenth most frequent cancer worldwide—has a heterogeneous natural
history and clinical behaviour. The predominant histological subtype, urothelial bladder …

In the present investigation, we sought to refine the classification of urothelial carcinoma by
combining information on gene expression, genomic, and gene mutation levels. For these …

Transitional cell (urothelial) carcinoma of the bladder is the second most common urologic
malignancy and is one of the best understood neoplasms, with relatively well-defined …

Despite the fact that the current histopathologic classification for bladder cancer has led to
improved concepts for the clinical management of the disease, key questions with regard to …

Fibroblast growth factor receptors (FGFRs) play diverse roles in the control of cell
proliferation, cell differentiation, angiogenesis and development. Activating the mutations of …

The four receptor tyrosine kinases (RTKs) within the family of Fibroblast Growth Factor
Receptors (FGFRs) are critical for normal development but also play an enormous role in …

Background Abnormal glycosylation in a variety of cancer types is involved in tumor
progression and chemoresistance. Glycosyltransferase C1GALT1, the key enzyme in …

Although many clinical and molecular markers for predicting outcomes in bladder cancer
(BC) have been reported, their application in clinical practice remains unclear. Bladder …